The reduction in inventories by pharmaceutical customers has slowed down the packaging manufacturer Gerresheimer at the start of the year. This comes as no surprise, as many pharma and biotech.
Already positive, the research from Jefferies and its analyst James Vane-Tempest still consider the stock as a Buy opportunity. The target price is unchanged at EUR 126.
In his latest research note, analyst James Vane-Tempest confirms his positive recommendation. The broker Jefferies is keeping its Buy rating. The target price has been revised upwards and is now set.